Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

Feb 12 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

Jacob Steven Leach, DexCom, Inc.'s President and CEO who will summarize our recent highlights and ongoing strategic initiatives. Followed by a financial review and outlook from Jereme M. Sylvain, our ...

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be ...

People have been riding the GLP-1 wave to achieve quick and significant weight loss. But given the drug’s effect on controlling type 2 diabetes, it’s no surprise that DexCom CEO Jake Leach wants to ...

Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with Type 2 diabetes and your fit-fluencer friend. Jake Leach, who took over as Dexcom CEO today, wants ...

Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous glucose monitoring system app, leading the FDA to issue its most serious recall notice. A “software defect in ...

Add Yahoo as a preferred source to see more of our stories on Google. Dexcom recalled an Android app for its G6 continuous glucose monitor because of a problem with the app stopping unexpectedly.

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...

A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device. Some patients reportedly experienced severe ...

San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a ...